[Clinical study of anti-leukotriene therapy with montelukast in bronchial asthma patients]. / Klinichnyi dosvid zastosuvannia antileikotriienovogo preparatu montelukastu v kompleksnomu likuvanni khvorykh na bronkhial'nu astmu.

Clinical and functional efficacy of the antileukotriene agent montelucast (singulair) was investigated in 30 patients with moderately severe bronchial asthma. Patients with a positive FEV1 response to montelukast (61.1%) demonstrated a higher blood level of IgE and sputum eosinophilia. Enhancement of bronchodilatatory effect secondary to the use of beta 2-agonist has been recordable in the wake of a 24-day montelucast treatment (10 mg o.d.).